Insider Trading Alert - MPW, ILMN And CHS Traded By Insiders
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Yesterday, March 18, 2015, 90 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $500.00 to $102,376,000.00.
Highlighted Stocks Traded by Insiders:
Medical Properties (MPW) - FREE Research Report
Aldag Edward K JR, who is Chairman, President and CEO at Medical Properties, sold 204,156 shares at $14.47 on March 18, 2015. Following this transaction, the Chairman, President and CEO owned 2.5 million shares meaning that the stake was reduced by 7.56% with the 204,156-share transaction.
The shares most recently traded at $14.68, up $0.21, or 1.43% since the insider transaction. Historical insider transactions for Medical Properties go as follows:
- 4-Week # shares bought: 1,000
- 4-Week # shares sold: 500
- 12-Week # shares bought: 1,000
- 12-Week # shares sold: 500
- 24-Week # shares bought: 1,000
- 24-Week # shares sold: 120,500
The average volume for Medical Properties has been 2.4 million shares per day over the past 30 days. Medical Properties has a market cap of $3.0 billion and is part of the financial sector and real estate industry. Shares are up 7.26% year-to-date as of the close of trading on Wednesday.
Medical Properties Trust, Inc. operates as a real estate investment trust (REIT) in the United States. It acquires, develops, and invests in healthcare facilities; and leases healthcare facilities to healthcare operating companies and healthcare providers. The stock currently has a dividend yield of 6.07%. The company has a P/E ratio of 50.0. Currently, there are 4 analysts who rate Medical Properties a buy, 1 analyst rates it a sell, and 3 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on MPW - FREE
rates Medical Properties as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full
Medical Properties Ratings Report
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Illumina (ILMN) - FREE Research Report
Henry Christian O, who is Sr VP & Chief Commercial Offic at Illumina, sold 5,001 shares at $191.59 on March 18, 2015. Following this transaction, the Sr VP & Chief Commercial Offic owned 43,059 shares meaning that the stake was reduced by 10.41% with the 5,001-share transaction.
Naclerio Nicholas, who is Sr VP, Corporate Development at Illumina, sold 6,590 shares at $193.94 on March 18, 2015. Following this transaction, the Sr VP, Corporate Development owned 48,047 shares meaning that the stake was reduced by 12.06% with the 6,590-share transaction.
The shares most recently traded at $199.75, up $5.81, or 2.91% since the insider transaction. Historical insider transactions for Illumina go as follows:
- 4-Week # shares sold: 45,798
- 12-Week # shares sold: 94,809
- 24-Week # shares sold: 111,732
The average volume for Illumina has been 1.2 million shares per day over the past 30 days. Illumina has a market cap of $28.0 billion and is part of the health care sector and drugs industry. Shares are up 5.69% year-to-date as of the close of trading on Wednesday.
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 82.1. Currently, there are 12 analysts who rate Illumina a buy, no analysts rate it a sell, and 6 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE
rates Illumina as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Chico's FAS (CHS) - FREE Research Report
Rhodes A Alexander, who is EVP-General Counsel at Chico's FAS, sold 1,980 shares at $18.04 on March 18, 2015. Following this transaction, the EVP-General Counsel owned 74,271 shares meaning that the stake was reduced by 2.6% with the 1,980-share transaction.
The shares most recently traded at $17.93, down $0.11, or 0.61% since the insider transaction. Historical insider transactions for Chico's FAS go as follows:
- 4-Week # shares sold: 51,952
- 12-Week # shares sold: 134,952
- 24-Week # shares sold: 134,952
The average volume for Chico's FAS has been 2.2 million shares per day over the past 30 days. Chico's FAS has a market cap of $2.8 billion and is part of the services sector and retail industry. Shares are up 11.04% year-to-date as of the close of trading on Wednesday.
Chico's FAS, Inc. operates as an omni-channel specialty retailer of women's private branded, casual-to-dressy clothing, intimates, complementary accessories, and other non-clothing items. The stock currently has a dividend yield of 1.72%. The company has a P/E ratio of 42.8. Currently, there are 9 analysts who rate Chico's FAS a buy, no analysts rate it a sell, and 10 rate it a hold.
Exclusive Offer: Get the latest Stock Analysis on CHS - FREE
rates Chico's FAS as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full
from
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
null